Researchers found that the HSD3B1 genotype may be a predictive biomarker for the use of androgen deprivation therapy or abiraterone in Japanese men with prostate cancer.

Cellanyx announced today that it has appointed Guy Fish MD MBA as a member of its Board and as acting CEO effective immediately. Dr. Fish joins Cellanyx after more than a 30year career in the health care industry most recently at th...

Sumit K. Subudhi MD PhD discusses the promise of the combination of nivolumab and ipilimumab in patients with metastatic castrationresistant prostate cancer and the challenges that lie ahead with this treatment approach.

Benjamin A. Gartrell MD discusses the promise of SM88 in this patient population as well as other therapeutic options that are emerging for various prostate cancer subtypes.

$ARAY Ph3 Randomized Trial Data Shows SBRT has Similar Acute Safety Profile to Conventional Radiation Therapy in Patients with Localized Prostate Cancer httpswww.prnewswire.comnewsreleasesphase3randomizedtrialdatashowssbrthassimilaracutesafetyprofiletoco...

The latest trial results are based on a larger patient population and were reported at the 2019 ASCO Genitourinary Cancers Symposium.

TAIPEI Taiwan February 21 2019 PRNewswire Foresee Pharmaceuticals Co. Ltd. 6576.TWO "Foresee" announced today the topline results of FP001 LMIS Leuprolide Mesylate Injectable Suspension 25 mg phase 3 clinical trial an openlabel singlearm...

Initial concerns that finasteride could increase risk of prostate cancer death have been found to be unwarranted in a longterm followup study.

The AIMlisted clinical stage biotechnology said its company broker Novum Securities issued 83333333 new ordinary shares at a price of 0.6p each with new and existing investors

Innovus Pharmaceuticals Inc. "Innovus Pharma" or the Company OTCQB Venture Market INNV an emerging overthecounter OTC consumer goods and specialty pharmaceutical company engaged in the commercialization licensing a...

The results of the doubleblind phase III trial were presented at the 2019 ASCO Genitourinary Cancers Symposium.

Minimally Invasive UroLift System Treatment Provides Rapid Symptom Relief and Improved Quality of Life While Preserving Sexual Function12 Teleflex Incorporated NYSETFX today announced that 100000 patients have been treated global...

The combination of ipilimumab with nivolumab shows activity in advanced disease. Medscape Medical News

CytoDyn Inc OTCQBCYDY CEO Dr. Nader Pourhassan and Chief Medical Officer Dr. Richard Pestell tell Proactive Investors its new lab in Philadelphia led by Dr. Pestell will conduct eight preclinical studies on melanoma pancreatic cancer breast cancer prostate...

We are the company that will achieve productive aging worldwide with advancing biomedical science Shinkowa Pharmaceutical Co. Ltd. main office Chuoku Tokyo Japan; CEO Megumi Tanaka has confirmed for the first time in the ...

New location offers more space for future expansions and is designed to inspire innovation of Lumicell technology through further employee collaboration Lumicell Inc. an innovation leader in molecular imaging within healthc...

Dr Sumit Subudhi speaks to ecancer at the 2019 ASCO Genitourinary Cancers Symposium about initial results from the CheckMate 650 study looking at nivolumab plus ipilimumab for the treatment of metastatic castrationresistant prostate cancer.He reports...

TUESDAY Feb. 19 2019 Metastasisfree survival is significantly longer among men with nonmetastatic castrationresistant prostate cancer treated with darolutamide versus placebo according to a phase 3 study published online Feb. 14 in the New...

Hit with a complete response letter from the US FDA for its antibiotic to treat ABSSSI Motif needs to raise...&160;&160;&160;